On March 14, ORTAT, a pharmaceutical plant of R-Pharm Group, released the first batch of Herceptin, a medicine, with DataMatrix code. 2D code on the package of the medicinal product fully complies with the requirements approved by the Ministry of Health of the Russian Federation on February 28, 2017, in the experiment on labeling certain types of medicines with control (identification) marks and monitoring of their circulation.
The implementation of a labeling system will eliminate the possibility for circulation of illegal and low-quality products by tracking the movement of each package of medicine from the manufacturer to the end consumer based on unique identifiers assigned to each package.
The labeling is applied in DataMatrix format according to GS1, an international standard, and includes the identification number of the package. Technically, the process of applying code and tracking is performed through the use of the iTrack system, which has been validated by the company.
At the first stage, R-Pharm plans to introduce the labeling for a pilot list of medicines. With the upgrade of equipment, the labeling will be applied to other medicines manufactured by the company, a significant part of which is included in the List of Vital and Essential Drugs (VED).